Physician profile
David Bonney
NPI 1548476385
$32,421.64
in general payments reported to CMS, 2019-2025
45 companies · $6,296 in 2025
The $6,296 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $2,060 · 2021: $3,796 · 2022: $3,587 · 2023: $5,622 · 2024: $8,492 · 2025: $6,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $3,850 · Education: $454 · Travel and Lodging: $32.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,072.41 |
| Consulting Fee | $3,850.00 |
| Education | $453.94 |
| Travel and Lodging | $32.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,942.91 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Abbvie INC. | $3,580.41 | 2019-2025 | Skyrizi, Rinvoq |
| Medimetriks Pharmaceuticals, INC. | $2,675.00 | 2020-2024 | Neo-Synalar, Sumadan Wash, Clindacin Etz |
| Janssen Biotech, INC. | $2,085.48 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $1,424.62 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $1,423.99 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $1,305.03 | 2019-2025 | |
| Journey Medical Corporation | $1,260.61 | 2019-2025 | Emrosi |
| Novartis Pharmaceuticals Corporation | $1,187.31 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $1,165.33 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,156.32 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $1,150.21 | 2021-2025 | Sotyktu |
| Ucb, INC. | $1,140.86 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $1,121.44 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $1,100.47 | 2021-2025 | Opzelura |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bonney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.